Search
Research
Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trialWe tested if disrupting iron utilisation by P. aeruginosa by adding the Tris-buffered chelating agent CaEDTA to nebulised tobramycin would enhance bacterial clearance and improve lung function in CF patients.
The Artificial Intelligence team at the Wal-yan Respiratory Research Centre is dedicated to delivering AI solutions for major challenges in respiratory healthcare and research.
Learn more about the Focus areas for the Wal-yan Respiratory Centre
Please contact the team early (at the stage of project design and budgeting) to ensure the most appropriate physiological test is selected with adequate funding.
Respiratory illness accounts for 12% of the age-standardised gap in mortality between Indigenous and non-Indigenous Australians.